12th Annual Biomarkers Congress

Oxford Global is proud to present its 12th Annual Biomarkers Congress taking place on the 21-22 February 2017 in Manchester. Our renowned congress will bring together over 300 attendees, speakers and vendor companies from pharmaceutical and biotechnology companies as well as academia.  

 

In line with the current industry trends, the flagship event this year focuses on the discovery, development and clinical development of biomarkers in Autoimmune, Immuno-oncology, Neuroscience, Oncology as well as Cardiovascular, Rheumatology, COPD, Rare Diseases and Microbiome. Our expert speakers will also cover innovations in Biomarker research such as imaging biomarkers and assay development, big data challenges in biomarker research, new advances in biomarker technologies and platforms; insights into the human proteome atlas, population genetics, systems biology and their implications in Biomarker development. Do not miss out on gaining insights on the role of biomarkers in clinical development, clinical trials and clinical diagnostics.  

 

Sponsored by over 50 international leading solution provider companies, the two-day congress highlights formal or informal discussions and pre-organised 1-2-1 meetings 

 

For the latest updates to the programme, our complimentary webinars, and attendance opportunities, please visit our website at www.biomarkers-congress.com. 

- Mark E. Curran, Vice President Systems Pharmacology and Biomarkers, 

Janssen R&D

- Johan Luthman, Vice President, Neuroscience Clinical Development, 

Eisai

- Meena Subramanyam, Vice President, Translational, Sciences & Technology, 

Biogen

- Amir Handzel, Director, Diagnostics, Translational and Personalized Medicine, 

AstraZeneca

- Jonathan Moggs, Director, Head of Molecular Toxicology, 

Novartis Institutes for Biomedical Research, Switzerland

- Andreas Schuppert, Director, Bayer Technology Services GmbH BTS-TD, 

Bayer

- Elizabeth Harrington, Director, Translational Science Oncology, 

AstraZeneca

-Gezim Lahu, Senior Director Global Head of Pharmacometrics, 

Takeda Pharmaceuticals International AG

- Stephen J Blakemore, Executive Director, Translational Medicine, 

Epizyme, Inc.

- Dongliang Ge, Director of Bioinformatics, 

Gilead Sciences Inc

- Gereon Lauer, Associate Director Discovery Biomarkers, 

Vertex Pharmaceuticals (Europe) Ltd